MX2020006237A - Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. - Google Patents
Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.Info
- Publication number
- MX2020006237A MX2020006237A MX2020006237A MX2020006237A MX2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- treatment
- diseases related
- dux4 expression
- dux4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Abstract
La presente invención se refiere a compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4, tales como distrofias musculares. También se refiere al uso de tales compuestos, o a métodos de uso de tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17207162 | 2017-12-13 | ||
PCT/EP2018/084802 WO2019115711A1 (en) | 2017-12-13 | 2018-12-13 | Compounds for treatment of diseases related to dux4 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006237A true MX2020006237A (es) | 2020-11-06 |
Family
ID=60673528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006237A MX2020006237A (es) | 2017-12-13 | 2018-12-13 | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10973820B2 (es) |
EP (2) | EP3723756A1 (es) |
JP (1) | JP2021506765A (es) |
KR (1) | KR20200098536A (es) |
CN (1) | CN111479570A (es) |
AU (1) | AU2018382974A1 (es) |
CA (1) | CA3083975A1 (es) |
DK (1) | DK3498278T3 (es) |
ES (1) | ES2791539T3 (es) |
IL (1) | IL275321A (es) |
MX (1) | MX2020006237A (es) |
WO (1) | WO2019115711A1 (es) |
ZA (1) | ZA202003407B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113350353A (zh) | 2015-03-23 | 2021-09-07 | 墨尔本大学 | 呼吸性疾病的治疗 |
US10973820B2 (en) * | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
TW202112368A (zh) * | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
JP2023503322A (ja) * | 2019-11-29 | 2023-01-27 | ファシオ インテレクチュアル プロパティ ビー.ヴイ. | Dux4発現に関連する疾患を処置するための新規化合物 |
CA3159250A1 (en) * | 2019-11-29 | 2021-06-03 | Facio Intellectual Property B.V. | New compounds for treatment of diseases related to dux4 expression |
UY39417A (es) | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
GB202019622D0 (en) * | 2020-12-11 | 2021-01-27 | Adorx Therapeutics Ltd | Antagonist compounds |
CN116888126A (zh) * | 2020-12-15 | 2023-10-13 | 北京原基华毅生物科技有限公司 | 一种酪蛋白激酶抑制剂的化合物 |
WO2023241552A1 (en) * | 2022-06-14 | 2023-12-21 | Gritscience Biopharmaceuticals Co., Ltd | Salt and/or crystal form for compounds as casein kinase inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060113754A (ko) | 2003-12-11 | 2006-11-02 | 아벤티스 파마슈티칼스 인크. | 카제인 키나제 Iε저해제로서 치환된 1H-피롤로[3,2-b,3,2-c, 및 2,3-c]피리딘-2-카복사미드 및 관련 유사체 |
FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
AU2010311035B2 (en) | 2009-10-28 | 2013-05-16 | Pfizer Inc. | Imidazole derivatives as casein kinase inhibitors |
ES2623387T3 (es) * | 2010-12-20 | 2017-07-11 | Pfizer Inc. | Nuevos compuestos de piridina condensada como inhibidores de la cinasa de caseína |
EP2546357A1 (en) | 2011-07-14 | 2013-01-16 | Erasmus University Medical Center Rotterdam | A new classifier for the molecular classification of multiple myeloma. |
WO2014081923A1 (en) | 2012-11-21 | 2014-05-30 | The Johns Hopkins University | Genomic classifiers for non-invasive identification of high grade prostate cancer with metastatic potential |
ES2489297B1 (es) * | 2013-01-22 | 2015-06-10 | Consejo Superior De Investigaciones Científicas (Csic) | Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas |
US9814728B2 (en) | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
CN106470699A (zh) * | 2014-02-03 | 2017-03-01 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 使用酪蛋白激酶i抑制剂以消耗干细胞的用途 |
SG11201606427SA (en) | 2014-02-07 | 2016-09-29 | Agency Science Tech & Res | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis |
ES2770693T3 (es) | 2014-06-19 | 2020-07-02 | Bristol Myers Squibb Co | Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon |
US10973820B2 (en) * | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
-
2018
- 2018-12-12 US US16/217,184 patent/US10973820B2/en active Active
- 2018-12-13 DK DK18212420.6T patent/DK3498278T3/da active
- 2018-12-13 KR KR1020207017659A patent/KR20200098536A/ko unknown
- 2018-12-13 CN CN201880080305.4A patent/CN111479570A/zh active Pending
- 2018-12-13 EP EP18814976.9A patent/EP3723756A1/en not_active Withdrawn
- 2018-12-13 JP JP2020531708A patent/JP2021506765A/ja active Pending
- 2018-12-13 EP EP18212420.6A patent/EP3498278B1/en active Active
- 2018-12-13 ES ES18212420T patent/ES2791539T3/es active Active
- 2018-12-13 CA CA3083975A patent/CA3083975A1/en active Pending
- 2018-12-13 AU AU2018382974A patent/AU2018382974A1/en not_active Abandoned
- 2018-12-13 MX MX2020006237A patent/MX2020006237A/es unknown
- 2018-12-13 WO PCT/EP2018/084802 patent/WO2019115711A1/en unknown
- 2018-12-13 US US16/771,232 patent/US20210177847A1/en not_active Abandoned
-
2020
- 2020-06-08 ZA ZA2020/03407A patent/ZA202003407B/en unknown
- 2020-06-11 IL IL275321A patent/IL275321A/en unknown
-
2022
- 2022-01-13 US US17/574,615 patent/US20220226318A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3498278A1 (en) | 2019-06-19 |
EP3723756A1 (en) | 2020-10-21 |
JP2021506765A (ja) | 2021-02-22 |
US20220226318A1 (en) | 2022-07-21 |
IL275321A (en) | 2020-07-30 |
WO2019115711A1 (en) | 2019-06-20 |
US10973820B2 (en) | 2021-04-13 |
US20210177847A1 (en) | 2021-06-17 |
EP3498278B1 (en) | 2020-03-18 |
CA3083975A1 (en) | 2019-06-20 |
DK3498278T3 (da) | 2020-04-20 |
KR20200098536A (ko) | 2020-08-20 |
ZA202003407B (en) | 2022-06-29 |
CN111479570A (zh) | 2020-07-31 |
AU2018382974A1 (en) | 2020-06-18 |
US20190175596A1 (en) | 2019-06-13 |
ES2791539T3 (es) | 2020-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
EP3675859A4 (en) | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2017007188A (es) | Compuesto antimicotico. | |
NZ761519A (en) | Nlrp3 modulators | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
IL270927B (en) | fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases | |
MX2019008375A (es) | Tiobenzoimidazol como fungicidas. | |
MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
PH12017501872A1 (en) | Methods of treating diseases |